Skip to content

Study · Measured the body's own peptide · 1991

3 results

Preferential increase in pituitary prolactin versus vasoactive intestinal peptide as a function of estradiol benzoate dose in the ovariectomized rat.

Carrillo AJ, Doherty PC, Guan XB, Sturtevant JR, Walro DG

Endocrinology1 Jan 1991Cited by 11 (Europe PMC)

PMID1986914 (opens in a new tab)DOI10.1210/endo-128-1-131 (opens in a new tab)PepBankPUB-01986914
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In ovariectomized rats, estradiol benzoate at 0.7 or 7 microgram did not change pituitary VIP content compared with controls.

    In plain wordsIn rats, low doses of estradiol did not change the body's own VIP in the pituitary compared with oil-treated controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePituitary VIP content after 0.7 or 7 microgram estradiol benzoate
    Study

    ratn: not reported in source

    Ovariectomized rat
    Comparator
    Oil-treated controls
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Injection of 0.7 or 7 microgram EB resulted in a significant increase in pituitary PRL without changing plasma PRL levels or pituitary VIP content compared to values in the control group.
    1 context sentence
    Summary · context
    To study this, pituitary VIP and PRL and plasma PRL were assayed in ovariectomized rats after treatment with estradiol benzoate (EB; 0.007, 0.07, 0.7, 7 or 70 microgram/rat).

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In ovariectomized rats, estradiol benzoate at 70 microgram increased pituitary VIP compared with control values.

    In plain wordsIn rats, the highest estradiol dose raised the body's own VIP in the pituitary compared with controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePituitary VIP content after 70 microgram estradiol benzoate
    Study

    ratn: not reported in source

    Ovariectomized rat
    Comparator
    Oil-treated controls
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Only treatment with 70 microgram EB produced a significant increase in both pituitary VIP and PRL as well as in plasma PRL compared to control values.
    1 context sentence
    Summary · context
    To study this, pituitary VIP and PRL and plasma PRL were assayed in ovariectomized rats after treatment with estradiol benzoate (EB; 0.007, 0.07, 0.7, 7 or 70 microgram/rat).

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Other

    In ovariectomized rats, estradiol benzoate at any dose had no significant effect on VIP content in the other tissues examined.

    In plain wordsIn rats, estradiol did not change the body's own VIP in the other tissues tested.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP content in hypothalamus, cortex, suprachiasmatic region and jejunum
    Study

    ratn: not reported in source

    Ovariectomized rat
    Comparator
    Oil-treated controls
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    EB treatment at any of the doses used had no significant effect on pituitary and plasma TSH or VIP content in any of the other tissues examined.
    2 context sentences
    Summary · context
    as well as VIP content in the medial basal hypothalamus, suprachiasmatic region, cerebral cortex, and jejunum.
    Summary · context
    To study this, pituitary VIP and PRL and plasma PRL were assayed in ovariectomized rats after treatment with estradiol benzoate (EB; 0.007, 0.07, 0.7, 7 or 70 microgram/rat).

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.